Quest Diagnostics Inks Two Deals in One Week

Quest Diagnostics Inks Two Deals in One Week

Quest Diagnostics (NYSE: DGX) had a busy week in late September, announcing two acquisitions. On September 25, Quest announced its purchase of the U.S. laboratory services business of Oxford Immunotec Global plc in Abingdon, UK. The U.S.-based business includes the T-SPOT.TB tuberculosis and the Accutix tick-borne disease testing services in Memphis, Tennessee and Norwood, Massachusetts. As part of the transaction, Oxford Immunotec will sell T-SPOT.TB test kits and related accessories to Quest under the terms of a long-term supply agreement, which would be effective at closing of the acquisition some time in the fourth quarter of 2018. Two days later, Quest went in a different direction... Read More »